Ensoma Focuses on Key Gene Therapy, Cuts Staff
Ensoma, a Boston biotech firm, cuts more jobs and stops other drug research to focus on its main gene therapy.
Ensoma is making big changes. The Boston-based company laid off more workers. It also paused other drug programs. This move helps the company focus on one main drug. That drug treats a rare immune disease.
This is not the first time Ensoma cut staff. Last November, the company let go of half its team. These new layoffs show Ensoma's strong commitment to its lead gene therapy. The company believes in this one treatment. It hopes this focus will help the drug succeed.
Ensoma wants to bring this important gene therapy to patients. Focusing resources on one program can speed up its development. This means the drug could reach those who need it sooner. It is a calculated risk for the company.
Source: FierceBiotech
More from Biotech
